Linezolid Glenmark

Linezolid, the active ingredient in Linezolid Glenmark, is an oxazolidinone presented as a tablet for oral use. It treats serious Gram‑positive bacterial infections, including methicillin‑resistant Staphylococcus aureus (MRSA) and vancomycin‑resistant Enterococcus (VRE), in adult patients and is commonly prescribed when alternative agents are ineffective.

GNH USA supplies Linezolid Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution across EU and other markets.

Linezolid is indicated for infections caused by Gram‑positive bacteria, particularly resistant strains. - Gram‑positive bacterial infections: effective against a broad range of susceptible organisms, reducing infection severity. - Methicillin‑resistant Staphylococcus aureus (MRSA): provides bacteriostatic activity to treat skin, soft‑tissue and pneumonia caused by MRSA. - Vancomycin‑resistant Enterococcus (VRE): used as an alternative therapy for infections where vancomycin is ineffective.

Like all antibiotics, linezolid may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset that may occur shortly after dosing. - Diarrhea: loose, watery stools that are usually self‑limiting but can cause dehydration. - Headache: transient cranial discomfort that often resolves without specific treatment.

Serious or Rare Side Effects: - Peripheral neuropathy: tingling, burning, or numbness in the hands or feet, potentially progressive with long‑term therapy. - Optic neuropathy: visual acuity loss or color‑vision disturbances, which may be irreversible if not identified early. - Severe thrombocytopenia: a marked drop in platelet count that can increase bleeding risk and may require medical intervention.

When prescribing linezolid, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust monitoring as the drug is excreted unchanged and may accumulate. - Hepatic dysfunction: use caution; liver disease can affect metabolism of concomitant drugs. - Prolonged therapy: monitor complete blood count regularly for signs of myelosuppression. - Serotonergic agents: avoid co‑administration due to risk of serotonin syndrome. - Pregnancy and lactation: assess risk‑benefit; limited data are available. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Linezolid can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis. - Rifampicin: strong enzyme inducer that can reduce linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring. - Ethanol: may increase the risk of disulfiram‑like reactions. - Anticonvulsants such as carbamazepine: may lower linezolid levels, necessitating therapeutic monitoring.